Onyx reiterated by Merrill at neutral

Onyx Pharmaceuticals Inc. was reiterated by Merrill Lynch analyst Eric Ende at a neutral rating in light of risk that Pfizer Inc. may include renal cell carcinoma data in its New Drug Application for Sutent for gastrointestinal stromal tumors, anticipated later this summer, which would be in direct competition with Onyx and Bayer AG's Sorafenib. Onyx shares Thursday sank $2.75, or 9.94%, to $24.91 on volume of 4,045,978 shares versus the three-month running average of 1,160,530 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.